FLUORESCEIN SODIUM


Trade Names	AK-FLUOR 10% AK-FLUOR 25% FLUORESCITE FUNDUSCEIN-25
Synonyms	Acid yellow 73 sodium salt Ak-Fluor C.i. 45350 C.i. acid yellow 73 Ci 45350 Fluor-amps Fluorescein disodium salt Fluorescein sodium Fluorescein, disodium salt Fluorescein, soluble Fluoresceinum natricum Fluorescite Fluorets Funduscein Funduscein-25 Ki202 Ki202(1) Ki202(2) Resorcinol phthalein sodium Retinofluor Soluble fluorescein Uranin Uranine Uranine wss Yellow 8
Status
Molecule Category	Salt-form
UNII	93X55PE38X
Parent Compound:	FLUORESCEIN


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	NJDNXYGOVLYJHP-UHFFFAOYSA-L
Smiles	O=C([O-])c1ccccc1-c1c2ccc(=O)cc-2oc2cc([O-])ccc12.[Na+].[Na+]
InChI	InChI=1S/C20H12O5.2Na/c21-11-5-7-15-17(9-11)25-18-10-12(22)6-8-16(18)19(15)13-3-1-2-4-14(13)20(23)24;;/h1-10,21H,(H,23,24);;/q;2*+1/p-2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H10Na2O5
Molecular Weight	376.28
AlogP	2.84
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	0.0
Polar Surface Area	72.83
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	25.0

Bioactivity

Mechanism of Action	Action	Reference
Disclosing agent	None	DailyMed

Cross References

Resources	Reference
ChEMBL	CHEMBL1628233
FDA SRS	93X55PE38X
PubChem	10608
SureChEMBL	SCHEMBL264060

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).